Boehringer Ingelheim has selected osapiens HUB for Maintenance as a global mobile platform for frontline maintenance teams across its regulated production network.
The first production site is live in Spain, with a multi-year rollout planned across Boehringer Ingelheim’s global manufacturing operations. The platform will be used to plan, execute, and document production-critical maintenance work in pharmaceutical environments where compliance, equipment availability, and traceability are central operating requirements.
The deployment is designed to integrate with SAP S/4HANA and support regulated workflows including GxP validation, audit trails, and electronic signatures. Maintenance orders, technical asset information, spare parts, procedures, and work instructions are made available through the platform, while field confirmations, time records, inspection results, and supporting documentation are transferred back into central systems.
Maintenance in pharmaceutical manufacturing is not a secondary engineering activity. It sits directly inside the control framework for production. Equipment must be maintained according to approved procedures, interventions must be recorded, deviations must be managed, and records must remain available for audit. A maintenance action can be technically correct while still creating compliance exposure if the associated documentation is incomplete.
Mobile platforms aim to close the gap between work execution and record creation. Instead of relying on paper records, disconnected spreadsheets, or delayed system updates, technicians can access instructions and capture evidence at the point of work. That can improve data quality while reducing the administrative lag that often separates maintenance activity from enterprise systems.
The move reflects a broader shift in pharmaceutical production toward digitised plant operations. Manufacturers are using digital tools to improve asset reliability, reduce downtime, strengthen compliance evidence, and standardise practices across global networks. Those goals are particularly important where sites have different legacy systems, local procedures, and equipment histories.
Recent UK pharmaceutical manufacturing investment, including Codis’ planned expansion of spray drying and oral solid dose capability in Nottingham, underlines the continued importance of production capacity. As facilities add more complex formulation and manufacturing work, plant reliability and validated maintenance processes become more valuable. Capacity depends on equipment that remains qualified, available, and documented.
Global standardisation can help Boehringer Ingelheim align maintenance practices across production sites, but that cannot be achieved by policy alone. Maintenance teams need systems that reflect approved procedures, asset structures, spare parts, safety requirements, and regulatory records. A common platform can support consistent processes while still allowing local configuration where site conditions require it.
Integration with SAP S/4HANA also gives maintenance data operational and commercial value. Asset histories, downtime trends, work order completion, spare parts usage, failure modes, and intervention times all inform capital planning and reliability improvement. When maintenance information remains trapped in local systems or paper files, it is harder to analyse performance across a network.
Digital maintenance does not replace engineering judgement. Pharmaceutical sites still depend on experienced technicians, reliability engineers, validation specialists, automation teams, and quality personnel. The value of mobile workflow software is in reducing administrative friction, guiding standard work, and providing stronger evidence for decisions. In regulated production, evidence is part of the process.
The Spanish deployment will provide the reference point for the wider rollout. Global success will depend on validation discipline, user adoption, integration quality, training, change management, and the ability to reflect real maintenance workflows rather than imposing generic software logic on complex production sites.
Pharmaceutical manufacturers are under pressure to improve resilience, reduce production interruptions, and maintain compliance while controlling operating cost. Standardised digital maintenance addresses one of the places where asset performance and regulatory confidence meet. For production-critical equipment, the record of work is increasingly part of the work itself.
